Press "Enter" to skip to content

FDA panel votes unanimously in favor of Horizon’s thyroid eye disease drug

If approved, teprotumumab, a type of immunotherapy, is expected to become a standard of care for the vision-threatening autoimmune disorder, which currently has no approved therapies.

Original source:

Also Read:   Bharat Biotech-ICMR developed Covaxin is safe, show preliminary phase I results